Open AccessPARP inhibitor treatment of advanced breast cancer beyond the BRCA-mutated type: a meta-analysis
Author(s) -
F. Yan,
Qi Jiang,
Minfei He,
Peng Shen
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2020-1175
Subject(s) - medicine , oncology , meta analysis , breast cancer , parp inhibitor , chemotherapy , regimen , randomized controlled trial , brca mutation , clinical trial , cancer , poly adp ribose polymerase , biochemistry , chemistry , polymerase , gene
Background: We conducted this meta-analysis to compare the efficacy and safety of PARP inhibitors with or without chemotherapy versus chemotherapy alone for advanced breast cancer. Methods: A meta-analysis and trial sequential analysis were performed using RevMan 5.2 analysis software. Results: Six eligible randomized clinical trials involving 2080 patients were included. Regimens containing PARP inhibitors were significantly associated with higher objective response rate, longer progression-free survival and overall survival. The PARP inhibitor regimen group had a significantly higher rate of grade ≥3 thrombocytopenia than the chemotherapy-only group. Conclusion: Regimens containing PARP inhibitors are effective and safe for BRCA-mutated advanced breast cancer patients. The efficacy appears to be only marginal in patients with BRCA status unselected.